We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+14.58%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$378M
AUM Growth
+$22.7M
Cap. Flow
-$2.63M
Cap. Flow %
-0.7%
Top 10 Hldgs %
31.74%
Holding
97
New
18
Increased
35
Reduced
31
Closed
13

Top Buys

Rank Stock Value
1
MASI
Masimo
MASI
+$7.85M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$5.39M
3
IMUX icon
Immunic
IMUX
+$4.26M
4
ETNB
89bio
ETNB
+$3.49M
5
SDC
SmileDirectClub, Inc. Class A Common Stock
SDC
+$3.31M

Top Sells

Rank Stock Value
1
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$8.03M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$6.37M
3
GNMK
GenMark Diagnostics, Inc
GNMK
+$4.89M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$3.45M
5
NVAX icon
Novavax
NVAX
+$2.74M

Sector Composition

Rank Sector Weight
1 Healthcare 92.08%
2 Technology 1.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FBRX icon
76
Forte Biosciences
FBRX
$1.57B
$606K 0.16%
+500
New +$331K
FOCL
77
EDAP TMS S.A.
FOCL
$178M
$575K 0.15%
+125,000
New +$431K
GDRX icon
78
GoodRx Holdings
GDRX
$1.22B
$556K 0.15%
+10,000
New +$529K
AMRN
79
Amarin Corp
AMRN
$297M
$489K 0.13%
5,808
-498
-8% -$59.7K
BCEL
80
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$489K 0.13%
+35,000
New +$522K
APRE icon
81
Aprea Therapeutics
APRE
$8.46M
$482K 0.13%
1,002
-1,000
-50% -$560K
WHWK
82
Whitehawk Therapeutics
WHWK
$269M
$450K 0.12%
+20,000
New +$421K
SNDX icon
83
Syndax Pharmaceuticals
SNDX
$1.77B
$443K 0.12%
30,005
+5
+0% +$76
OM icon
84
Outset Medical
OM
$84.6M
$350K 0.09%
+467
New +$384K
AKRO
85
DELISTED
Akero Therapeutics
AKRO
– –
-95,000
Closed -$2.37M
APYX icon
86
Apyx Medical
APYX
$126M
– –
-70,497
Closed -$391K
CLPT icon
87
ClearPoint Neuro
CLPT
$463M
– –
-25,078
Closed -$89K
HAE icon
88
Haemonetics
HAE
$4.16B
– –
-30,147
Closed -$2.7M
IRMD icon
89
iRadimed
IRMD
$1.12B
– –
-94,717
Closed -$2.2M
KPTI icon
90
Karyopharm Therapeutics
KPTI
$46M
– –
-8,053
Closed -$2.29M
MBIO icon
91
Mustang Bio
MBIO
$4.59M
– –
-405
Closed -$965K
MRNA icon
92
Moderna
MRNA
$25.4B
– –
-10,000
Closed -$642K
XBI icon
93
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.5B
– –
-75,000
Closed -$8.4M
PVLA
94
Palvella Therapeutics
PVLA
$2.23B
– –
-5,736
Closed -$1.42M
MRNS
95
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-25,000
Closed -$254K
SGEN
96
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-37,500
Closed -$6.37M
BHVN
97
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-25,000
Closed -$1.83M
1 2 3
4

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q3 2020 Portfolio in Review

As of Q3 2020, Parkman Healthcare Partners held 97 positions worth $378M, up 6.4% from $355M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Parkman Healthcare Partners's Q3 2020 filing shows 18 new, 35 increased, 31 reduced and 13 closed positions. Its largest new stake was Masimo: 35,000 shares worth $8.26M. The largest sale was GW Pharmaceuticals Plc American Depositary Shares, an estimated $8.03M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 90% a quarter earlier, followed by Technology.

  • Parkman Healthcare Partners's largest Q3 2020 buy was Masimo: 35,000 shares worth $8.26M.
  • Parkman Healthcare Partners added most to Immunic in Q3 2020, an estimated $4.26M increase.
  • Parkman Healthcare Partners's biggest Q3 2020 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $8.03M.
  • Parkman Healthcare Partners fully exited Seagen Inc. Common Stock in Q3 2020, selling an estimated $6.37M.
  • Parkman Healthcare Partners's ten largest holdings make up 32% of its $378M portfolio in Q3 2020.
  • Parkman Healthcare Partners opened 18 new positions and closed 13 in Q3 2020.
  • Parkman Healthcare Partners's portfolio value rose 6.4% quarter-over-quarter to $378M.

Based on Parkman Healthcare Partners's 13F filing for Q3 2020, filed 13 Nov 2020.